Viskase Adopts Section 382 Tax Benefits Rights Plan

Viskase Holdings ( (ENZN) ) just unveiled an announcement.

On April 30, 2026, Viskase’s board declared a dividend of one right for each common share and on May 5, 2026 adopted a Section 382 tax benefits preservation plan and related preferred stock designation, aiming to prevent an ownership change that would severely limit the use of its substantial U.S. federal and state net operating loss carryforwards. The plan, which generally deters new investors from acquiring 4.9% or more of the stock or existing large holders from increasing their stakes by threatening significant dilution, is set to expire on May 4, 2029 and is designed to safeguard the economic value of Viskase’s tax assets and, by extension, shareholder value.

Under the Section 382 Rights Plan, rights initially trade with common shares and become exercisable if a holder crosses the 4.9% threshold, enabling other investors to buy stock at a 50% discount or receive shares via an exchange, while also giving the board broad discretion to exempt certain investors and transactions. By tightening control over ownership shifts while carving out exemptions for specified insiders and strategic holders, Viskase signals a defensive but value-focused posture that could stabilize its capital structure, protect its NOL-driven tax shield and influence how activist or strategic investors approach accumulating positions in the company over the coming years.

More about Viskase Holdings

Viskase Holdings, Inc., formerly Enzon Pharmaceuticals, operates through subsidiaries in the casing products segment of the food industry. The company is a worldwide leader in producing and selling cellulosic, fibrous and plastic casings used by the processed meat and poultry industry, giving it a specialized position in a niche but globally distributed market.

Average Trading Volume: 1,287

Technical Sentiment Signal: Sell

Current Market Cap: $93.16M

Find detailed analytics on ENZN stock on TipRanks’ Stock Analysis page.